Revolution Medicines (RVMD) Assets Average (2020 - 2026)
Revolution Medicines (RVMD) posted quarterly Assets Average of $2.3 billion for Q1 2026, down 6.41% year-over-year from $2.5 billion in Q1 2025, and little changed quarter-over-quarter from $2.3 billion in Q4 2025.
Revolution Medicines (RVMD) Assets Average (2020 - 2026) Analysis & Trends
Revolution Medicines' Assets Average history runs 7 years deep, the most recent figure standing at $2.3 billion for Q1 2026.
- In Q1 2026, Assets Average fell 6.41% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $2.3 billion (down 6.41% YoY), while the FY2025 annual figure was $2.5 billion, up 6.34% from the prior year.
- Assets Average for Q1 2026 stood at $2.3 billion, roughly flat from $2.3 billion in the prior quarter.
- The five-year high for Assets Average was $2.5 billion in Q1 2025, with the low at $657.8 million in Q2 2022.
- The 5-year median for Assets Average is $1.1 billion (2023), against an average of $1.5 billion.
- The sharpest annual moves came in 2022 and 2025: Assets Average slipped 17.03% in 2022, then surged 157.38% in 2025.
- Revolution Medicines' Assets Average stood at $818.9 million in 2022, then soared by 85.97% to $1.5 billion in 2023, then surged by 41.87% to $2.2 billion in 2024, then advanced by 6.6% to $2.3 billion in 2025, then advanced by 0.04% to $2.3 billion in 2026.
- Business Quant data shows RVMD's Assets Average at $2.3 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.29 Bn |
| Mar 31, 2026 | 2.30 Bn |
| Dec 31, 2025 | 2.30 Bn |
| Sep 30, 2025 | 2.34 Bn |
| Jun 30, 2025 | 2.40 Bn |
| Mar 31, 2025 | 2.46 Bn |
| Dec 31, 2024 | 2.16 Bn |
| Sep 30, 2024 | 909.45 Mn |
| Jun 30, 2024 | 982.13 Mn |
| Mar 31, 2024 | 1.99 Bn |
| Dec 31, 2023 | 1.52 Bn |
| Sep 30, 2023 | 1.03 Bn |
| Jun 30, 2023 | 1.07 Bn |
| Mar 31, 2023 | 942.59 Mn |
| Dec 31, 2022 | 818.92 Mn |
| Sep 30, 2022 | 729.36 Mn |
| Jun 30, 2022 | 657.79 Mn |
| Mar 31, 2022 | 710.38 Mn |
| Dec 31, 2021 | 736.48 Mn |
| Sep 30, 2021 | 754.51 Mn |